Shim Hunbo, Percy Edward, Hirji Sameer, Kaneko Tsuyoshi
1861 Division of Cardiac Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
1861 Division of Cardiovascular Surgery, University of British Columbia, Vancouver, Canada.
Innovations (Phila). 2020 Jan/Feb;15(1):26-35. doi: 10.1177/1556984519890602. Epub 2020 Jan 5.
Transcatheter mitral valve repair devices borrow from the concept of surgical edge-to-edge approximation and are becoming increasingly used in patients with both primary and functional mitral regurgitation. The application of these new devices is expanding globally; however, debates between which patients are amenable to surgery vs. percutaneous approaches are ongoing. As new trials and regulatory approvals have evolved, the indications for transcatheter approaches have expanded, in a way that is complementaty to existing indications for surgical repair. In general, the treatment of mitral regurgitation should be stratified based on underlying pathophysiology and anatomy by a multidisciplinary team including cardiac surgeons and interventional cardiologists. This review aims to provide practical approaches to patient selection and treatment strategies for mitral regurgitation based on historical data and recently published trials, with a focus on the distinction between surgical and transcatheter mitral therapies.
经导管二尖瓣修复装置借鉴了外科边缘对边缘缝合的理念,越来越多地应用于原发性和功能性二尖瓣反流患者。这些新装置的应用正在全球范围内不断扩大;然而,关于哪些患者适合手术治疗与经皮治疗的争论仍在继续。随着新试验和监管批准的不断发展,经导管治疗方法的适应症有所扩大,这在某种程度上补充了现有的外科修复适应症。一般来说,二尖瓣反流的治疗应根据潜在的病理生理学和解剖结构,由包括心脏外科医生和介入心脏病学家在内的多学科团队进行分层。本综述旨在根据历史数据和最近发表的试验,提供二尖瓣反流患者选择和治疗策略的实用方法,重点是外科和经导管二尖瓣治疗的区别。